~46 PATENT ABSTRACTS

4900723 4902614

M E T H O D O F P R E V E N T I N G O R R E D U C I N G V E N O U S

T H R O M B O S I S U S I N G A T H R O M B O X A N E A2 R E C E P T O R

A N T A G O N I S T I N C O N J U N C T I O N W I T H H E P A R I N A N D

C O M B I N A T I O N

William A Schumacher assigned to E R Squibb & Sons Inc

A method is provided for preventing or reducing deep vein thrombosis and/or pulmonary em- bolism by administering a thromboxane A2 receptor antagonist in conjunction with heparin. A combination of thromboxane A2 receptor an- tagonist and heparin is also provided.

M O N O C L O N A L A N T I B O D Y T O H U M A N P R O T E I N C

Kcnji Wakabayashi, Yoshihiko Sumi, Yataro Ichikawa, Yoichi Sakata, Jun Mimuro, Nobuo Aoki, Hino, Japan assigned to Teijin Limited

A monoclonal antibody which is specific to human protein C which has calcium bound at the gammacarboxyglutamic acid(Gla) domain and does not recognize human protein C which is not bound to calcium at the Gla domain. The mono- clonal antibody is used in an immunoassay method for determining human protein C having a Gla domain and in a method for recovering human protein C having a Gal domain.

4900724 4902615

T U M O R N E C R O S I S F A C T O R I N D U C I N G S U B S T A N C E D E R I V E D

F R O M A C I D - F A S T B A C T E R I A

Yoshiko Kato, Hiroko Usami, Hyogo, Japan as- signed to Sawai Pharmaceutical Co Ltd; Chugai Seiyaku Kabushiki Kais

The present invention provides a novel am- phipathic substance having tumor necrosis fac- tor (TNF) inducing activity. This substance is an amphipathic substance obtained by extraction from several kinds of acid-fast bacteria, and has excellent TNF inducing activity. The toxicity of the substance is much lower than that of the con- ventional amphipathic substances having TNF inducing activity.

4902288

I M P L A N T A B L E I M M U N O T H E R A P Y S Y S T E M U S I N G S T I M U L A T E D C E L L S

Marylou Ingram

This invention involves treating a patient having a tumor by introducing at the area of the tumor immunologically active cells which are an- tagonistic to the tumor. The cells being con- tained in a matrix which allows for cell migration. For example the matrix can be a blood clot.

D E T E C T I O N O F H U M A N C A N C E R C E L L S W I T H

A N T I B O D I E S T O H U M A N C A N C E R N U C L E O L A R A N T I G E N

P120

James W Freeman, Harri Busch assigned to Bio- sciences Corporation of Texas

Tumor nucleoli were treated with polyclonal antisera to normal human tissue nucleoli to block determinants common to tumor and nor- mal tissue nucleoli. Immunization of mice with these immune-complexes resulted in the develop- ment of a monoclonal antibody (FB2) to a novel nucleolar proliferation associated antigen which has a molecular weight of about 120 kD and a pl of about 4.5. By indirect immunofluorescence, antibody FB2 produced bright nucleolar staining in a variety of malignant tumors, in- cluding cancers of the breast, liver, gastroin- testinal tract, genitourinary tract, blood, lung and brain. Specific nucleolar immunofluores- cence was not detectable in most normal tissues, although it was weakly detectable in some pro- liferating nonmalignant tissues including spermatognnia of the tests, ductal regions of hypertrophied prostate, and PHA stimulated lymphocytes. Disclosed are characterizations and methods for isolating nucleolar antigen p120, characterizations and methods for pro- ducing antibodies including monoclonal anti- body having binding specificity to nucleolar antigen p 120, and diagnostic procedures and kits useful for detecting human cancer cells.